129 related articles for article (PubMed ID: 8753770)
1. Anti-HIV and anti-HBV activity and resistance profile of 2',3'-dideoxy-3'-thiacytidine (3TC) and its arylphosphoramidate derivative CF 1109.
Balzarini J; Wedgwood O; Kruining J; Pelemans H; Heijtink R; De Clercq E; McGuigan C
Biochem Biophys Res Commun; 1996 Aug; 225(2):363-9. PubMed ID: 8753770
[TBL] [Abstract][Full Text] [Related]
2. Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme.
Back NK; Nijhuis M; Keulen W; Boucher CA; Oude Essink BO; van Kuilenburg AB; van Gennip AH; Berkhout B
EMBO J; 1996 Aug; 15(15):4040-9. PubMed ID: 8670908
[TBL] [Abstract][Full Text] [Related]
3. Phosphatidyl-2',3'-dideoxy-3'-thiacytidine: synthesis and antiviral activity in hepatitis B-and HIV-1-infected cells.
Xie H; Voronkov M; Liotta DC; Korba BA; Schinazi RF; Richman DD; Hostetler KY
Antiviral Res; 1995 Oct; 28(2):113-20. PubMed ID: 8585765
[TBL] [Abstract][Full Text] [Related]
4. Genotypic and phenotypic characterization of HIV-1 isolated from patients receiving (--)-2',3'-dideoxy-3'-thiacytidine.
Kavlick MF; Shirasaka T; Kojima E; Pluda JM; Hui F; Yarchoan R; Mitsuya H
Antiviral Res; 1995 Oct; 28(2):133-46. PubMed ID: 8585767
[TBL] [Abstract][Full Text] [Related]
5. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase.
Tisdale M; Kemp SD; Parry NR; Larder BA
Proc Natl Acad Sci U S A; 1993 Jun; 90(12):5653-6. PubMed ID: 7685907
[TBL] [Abstract][Full Text] [Related]
6. Marked inhibitory activity of non-nucleoside reverse transcriptase inhibitors against human immunodeficiency virus type 1 when combined with (-)2',3'-dideoxy-3'-thiacytidine.
Balzarini J; Pelemans H; Pérez-Pérez MJ; San-Félix A; Camarasa MJ; De Clercq E; Karlsson A
Mol Pharmacol; 1996 May; 49(5):882-90. PubMed ID: 8622638
[TBL] [Abstract][Full Text] [Related]
7. Use of the hepatitis B virus recombinant baculovirus-HepG2 system to study the effects of (-)-beta-2',3'-dideoxy-3'-thiacytidine on replication of hepatitis B virus and accumulation of covalently closed circular DNA.
Delaney WE; Miller TG; Isom HC
Antimicrob Agents Chemother; 1999 Aug; 43(8):2017-26. PubMed ID: 10428929
[TBL] [Abstract][Full Text] [Related]
8. Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase.
Wainberg MA; Drosopoulos WC; Salomon H; Hsu M; Borkow G; Parniak M; Gu Z; Song Q; Manne J; Islam S; Castriota G; Prasad VR
Science; 1996 Mar; 271(5253):1282-5. PubMed ID: 8638110
[TBL] [Abstract][Full Text] [Related]
9. Mechanistic studies show that (-)-FTC-TP is a better inhibitor of HIV-1 reverse transcriptase than 3TC-TP.
Feng JY; Shi J; Schinazi RF; Anderson KS
FASEB J; 1999 Sep; 13(12):1511-7. PubMed ID: 10463941
[TBL] [Abstract][Full Text] [Related]
10. Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex.
Wainberg MA; Salomon H; Gu Z; Montaner JS; Cooley TP; McCaffrey R; Ruedy J; Hirst HM; Cammack N; Cameron J
AIDS; 1995 Apr; 9(4):351-7. PubMed ID: 7540846
[TBL] [Abstract][Full Text] [Related]
11. Anti-hepatitis B virus activity and metabolism of 2',3'-dideoxy-2',3'-didehydro-beta-L(-)-5-fluorocytidine.
Zhu YL; Dutschman DE; Liu SH; Bridges EG; Cheng YC
Antimicrob Agents Chemother; 1998 Jul; 42(7):1805-10. PubMed ID: 9661025
[TBL] [Abstract][Full Text] [Related]
12. Concomitant combination therapy for HIV infection preferable over sequential therapy with 3TC and non-nucleoside reverse transcriptase inhibitors.
Balzarini J; Pelemans H; Karlsson A; De ClercQ E; Kleim JP
Proc Natl Acad Sci U S A; 1996 Nov; 93(23):13152-7. PubMed ID: 8917560
[TBL] [Abstract][Full Text] [Related]
13. Retention of marked sensitivity to (S)-4-isopropoxycarbonyl-6-methoxy-3-(methylthiomethyl)-3,4-di hydroquin oxaline-2(1H)-thione (HBY 097) by an azidothymidine (AZT)-resistant human immunodeficiency virus type 1 (HIV-1) strain subcultured in the combined presence of quinoxaline HBY 097 and 2',3'-dideoxy-3'-thiacytidine (lamivudine).
Balzarini J; Pelemans H; Riess G; Roesner M; Winkler I; De Clercq E; Kleim JP
Biochem Pharmacol; 1998 Mar; 55(5):617-25. PubMed ID: 9515572
[TBL] [Abstract][Full Text] [Related]
14. Antiviral and cellular metabolism interactions between Dexelvucitabine and lamivudine.
Hernandez-Santiago BI; Mathew JS; Rapp KL; Grier JP; Schinazi RF
Antimicrob Agents Chemother; 2007 Jun; 51(6):2130-5. PubMed ID: 17403996
[TBL] [Abstract][Full Text] [Related]
15. Antiviral activity of 5'-O-carbonate-2',3'-dideoxy-3'-thiacytidine prodrugs against hepatitis B virus in HepG2 2.2.15 cells.
Gagey D; Ravetti S; Castro EF; Gualdesi MS; Briñon MC; Campos RH; Cavallaro LV
Int J Antimicrob Agents; 2010 Dec; 36(6):566-9. PubMed ID: 20947311
[TBL] [Abstract][Full Text] [Related]
16. Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.
Schinazi RF; Lloyd RM; Nguyen MH; Cannon DL; McMillan A; Ilksoy N; Chu CK; Liotta DC; Bazmi HZ; Mellors JW
Antimicrob Agents Chemother; 1993 Apr; 37(4):875-81. PubMed ID: 7684216
[TBL] [Abstract][Full Text] [Related]
17. The K65R mutant reverse transcriptase of HIV-1 cross-resistant to 2', 3'-dideoxycytidine, 2',3'-dideoxy-3'-thiacytidine, and 2',3'-dideoxyinosine shows reduced sensitivity to specific dideoxynucleoside triphosphate inhibitors in vitro.
Gu Z; Fletcher RS; Arts EJ; Wainberg MA; Parniak MA
J Biol Chem; 1994 Nov; 269(45):28118-22. PubMed ID: 7525567
[TBL] [Abstract][Full Text] [Related]
18. The hepatitis B virus M539V polymerase variation responsible for 3TC resistance also confers cross-resistance to other nucleoside analogues.
Ladner SK; Miller TJ; Otto MJ; King RW
Antivir Chem Chemother; 1998 Jan; 9(1):65-72. PubMed ID: 9875378
[TBL] [Abstract][Full Text] [Related]
19. High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase.
Boucher CA; Cammack N; Schipper P; Schuurman R; Rouse P; Wainberg MA; Cameron JM
Antimicrob Agents Chemother; 1993 Oct; 37(10):2231-4. PubMed ID: 7504909
[TBL] [Abstract][Full Text] [Related]
20. Structural features in common of HBV and HIV-1 resistance against chirally-distinct nucleoside analogues entecavir and lamivudine.
Yasutake Y; Hattori SI; Tamura N; Matsuda K; Kohgo S; Maeda K; Mitsuya H
Sci Rep; 2020 Feb; 10(1):3021. PubMed ID: 32080249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]